-+ 0.00%
-+ 0.00%
-+ 0.00%

Market Chatter: AstraZeneca In Talks for $400 Billion Combination With US Peer BMS

MT Newswires·08/02/2026 23:16:34
Listen to the news
11:16 PM EDT, 08/02/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) is discussing a potential merger with Bristol Myers Squibb, or BMS, for a combined valuation of $400 billion, London's Financial Times reported Sunday, citing people familiar with the matter. The talks between UK drugmaker AstraZeneca and its US peer have taken place in recent months, according to the report. The people said a potential deal could be announced in the near future while cautioning that it may still be delayed or fall apart. AstraZeneca declined to comment, while BMS did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)